Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

(2010) Andrew D. Goodman et al.   ANNALS OF NEUROLOGY

Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis

(2010) Richard A. Rudick et al.   ARCHIVES OF NEUROLOGY

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

(2010) S. Belachew et al.   EUROPEAN JOURNAL OF NEUROLOGY

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

(2009) M. Hutchinson et al.   JOURNAL OF NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Impact of multiple sclerosis relapses on progression diminishes with time

(2009) H. Tremlett et al.   NEUROLOGY

Contribution of relapses to disability in multiple sclerosis

(2008) C. Hirst et al.   JOURNAL OF NEUROLOGY

Disability as an outcome in MS clinical trials

(2008) G. C. Ebers et al.   NEUROLOGY